文献速递瓣膜外科

TAVR与SAVR在低中危患者中的试验结果能否推广至真实世界人群

Transcatheter versus surgical aortic valve replacement in low- to intermediate-risk patients: Do DEDICATE trial outcomes translate to real-world populations?
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-09-22

本研究评估DEDICATE随机试验结果能否推广至荷兰真实世界人群,将TAVR试验组和SAVR试验组患者与荷兰心脏登记处SAVR登记队列进行倾向性评分匹配。结果显示,在匹配队列中,SAVR试验组患者的复合终点和卒中发生率高于SAVR登记组,而TAVR试验组患者1年死亡率低于SAVR登记组;将试验结果加权至登记人群后,TAVR的1年死亡率绝对风险降低幅度减弱。

要点

  • SAVR试验组患者复合终点和卒中风险高于真实世界SAVR登记组,提示需谨慎外推试验相对效应。
  • TAVR试验组患者1年死亡率低于SAVR登记组,但加权后绝对获益减弱。
  • 将随机试验结果推广至真实世界人群时,相对效应可能可重现,但绝对获益可能被高估。

核心结论

  • 在倾向性评分匹配分析中,SAVR登记组患者的复合死亡/卒中及卒中发生率低于SAVR试验组参与者,提示将试验相对效应外推至该人群需谨慎。
  • 对于死亡率,试验的相对效应可被重现,但TAVR在登记人群中的绝对获益减弱。

研究设计与样本

  • 研究数据包括DEDICATE随机对照试验数据(TAVR试验组和SAVR试验组队列)及荷兰心脏登记处SAVR登记队列。
  • 主要终点为1年全因死亡或卒中的复合终点,次要终点为死亡和卒中。
  • 采用倾向性评分匹配将TAVR试验组和SAVR试验组患者分别与SAVR登记组患者匹配,并进行基于模型和基于权重的可移植性分析。

主要发现

  • 应用试验标准后,SAVR登记组3389例患者符合条件,试验组共纳入1211例患者(TAVR组654例,SAVR组557例)。
  • 符合试验标准的SAVR登记组患者较年轻且合并症较少。
  • 倾向性评分匹配后,TAVR试验组与SAVR登记组匹配队列1150例,SAVR试验组与SAVR登记组匹配队列892例。

临床怎么用

  • 在低中危主动脉瓣狭窄患者中,将随机试验获得的TAVR相对效应外推至真实世界人群时需谨慎,尤其需注意绝对获益可能高估。
  • 临床决策应结合真实世界人群特征评估TAVR与SAVR的获益风险比,而非直接套用试验结果。

局限性

  • 研究为基于登记数据的可移植性分析,非随机对照设计,可能存在未测量混杂。
  • SAVR登记组中符合试验标准的患者较年轻且合并症较少,可能限制结果外推。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the transportability of the randomized DEDICATE (Randomized, Multicenter, Event-Driven Trial of TAVI versus SAVR in Patients with Symptomatic Severe Aortic-Valve Stenosis) trial results, comparing surgical aortic valve replacement (SAVR) with transcatheter aortic valve replacement (TAVR) in low- to intermediate-risk patients, with an external Dutch population derived from the Netherlands Heart Registration. METHODS: Data sources included the DEDICATE-RCT data (TAVR-trial, SAVR-trial cohorts) and the Netherlands Heart Registration (SAVR-registry cohort). The primary end point was composite of all-cause mortality or stroke at 1 year; secondary end points were mortality and stroke. As-treated TAVR-trial and SAVR-trial patients were propensity-score (PS) matched to SAVR-registry patients. Model-based and weighting-based transportability analyses were performed. RESULTS: After we applied trial criteria, 3389 patients from the SAVR registry were eligible and 1211 patients from the trial (654 TAVR; 557 SAVR) were included. Patients from the SAVR registry who were eligible for the trial were younger and had fewer comorbidities. PS matching of TAVR-trial to SAVR-registry cohorts yielded 1150 patients, and matching of the SAVR-trial to SAVR-registry cohorts yielded 892 patients. In PS-matched cohorts, SAVR-trial patients experienced more composite events (hazard ratio [HR], 1.63; 1.02-2.62, P = .04) and strokes (HR, 2.96; 1.37-6.37, P = .01) than SAVR-registry patients, with comparable mortality (HR, 1.15; 0.65-2.02, P = .63). TAVR-trial (vs SAVR-registry) patients had lower 1-year mortality (HR, 0.46; 0.24-0.87, P = .02). Transported absolute risk reduction (ARR) of 1-year mortality of TAVR was attenuated when the trial was reweighted to resemble the registry (ARRtransported: 2.2% [0.1-4.2]; ARRtrial: 3.7% [1.4-6.7]). CONCLUSIONS: In PS-matched analyses, patients from the SAVR registry showed lower combined mortality/stroke and stroke rates than participants in the SAVR trial, suggesting caution in transporting trial-derived relative effects to this population. For mortality, the relative trial effects could be reproduced, but absolute benefit of TAVR was diminished in the registry population.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Daeter EJ, Roefs MM, Post RAJ, et al. Transcatheter versus surgical aortic valve replacement in low- to intermediate-risk patients: Do DEDICATE trial outcomes translate to real-world populations? J Thorac Cardiovasc Surg. 2026. PMID: 42772371. doi:10.1016/j.jtcvs.2026.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。